Fosclevudine alafenamide clinical trials
Also written ATI-2173.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses fosclevudine alafenamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Antios Therapeutics, Inc (6)
Often tested with
Tested in the same studies.
Tenofovir (1) · Midazolam (1) · Clarithromycin (1) · Imdusiran sodium (1) · Imdusiran (1) · Vebicorvir (1)
Studies
Open first, then newest update. How each study uses fosclevudine alafenamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus CoinfectionTerminatedPhase 2Antios Therapeutics, IncNCT04847440Written as ATI-2173
- Ethnobridging Study in Healthy Volunteers, Chinese and Japanese SubjectsTerminatedPhase 1Antios Therapeutics, IncNCT05298332Written as ATI-2173 50 mg
- A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus InfectionTerminatedPhase 2Antios Therapeutics, IncNCT05238844Written as ATI-2173 25mg
- A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy SubjectsCompletedPhase 1Antios Therapeutics, IncNCT05137548Written as ATI-2173 50 mg
- A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy SubjectsCompletedPhase 1Antios Therapeutics, IncNCT05137600Written as ATI-2173
- A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus InfectionCompletedPhase 1Antios Therapeutics, IncNCT04248426Written as ATI-2173
Codes
What other systems call fosclevudine alafenamide · ClinicalTrials.gg INT015421
- UNII (FDA) 77AP23J0GHFOSCLEVUDINE ALAFENAMIDEOne source FDA
- NCI Thesaurus C190347Fosclevudine AlafenamideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 77AP23J0GH | FOSCLEVUDINE ALAFENAMIDE | One source FDA |
| NCI Thesaurus | C190347 | Fosclevudine Alafenamide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.